An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process

In Part 2 of this exclusive interview, Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, tells HBW Insight what the association is doing to improve the prescription-to-OTC switch process in Germany. 

ElmarKroth
The BAH's scientific director Elmar Kroth • Source: BAH

The BAH’s initiative to shift the switching process in the country from a substance-based to a product-based classification system is explored in this second part of our two-part interview with the association’s scientific director, Elmar Kroth. (Also see "An Expert’s Guide To Switching In Germany, Part 1: Navigating The Reclassification Process" - HBW Insight, 10 December, 2018.)

Kroth also discusses the BAH’s proposals to introduce three-year data exclusivity periods for products switched within such a system, and to offer pre-application scientific advice to firms looking to switch...

More from Rx-to-OTC Switch

More from Health